# Resting CD4 regulatory T cell and neuroblastoma: A Mendelian randomization study

## TL;DR

This study finds that higher levels of resting CD4 regulatory T cells are linked to neuroblastoma progression and suggests papain as a potential chemotherapy drug.

## Contribution

The study identifies a novel correlation between resting CD4 regulatory T cells and neuroblastoma using Mendelian randomization and proposes papain as a potential treatment.

## Key findings

- Resting CD4 regulatory T cell levels are positively correlated with neuroblastoma occurrence and development.
- Papain is suggested as a chemotherapy drug that interacts with CD4+ T lymphocytes in neuroblastoma treatment.

## Abstract

Neuroblastoma (NB) is a common extracranial solid tumor in children, and currently our understanding of the molecular mechanisms underlying tumor progression is not very thorough. In clinical practice, although the prognosis and survival rates of NB patients in the low‐risk and medium‐risk groups are still acceptable, the prognosis and survival rates of NB patients in the high‐risk group are extremely poor. Therefore, improving awareness of NB tumors is crucial for improving the treatment status of NB patients in clinical practice. So we collected common tumor exposure factors and performed multiple Mendelian randomization (MR) analysis on NB, and ultimately determined that the increase in Resting CD4 regulatory T cell was positively correlated with the occurrence and development of NB. In addition, we also used the network pharmacology algorithm proximity to screen the NB chemotherapy drug papain and reasonably speculated that there is an interaction between papain and CD4 regulatory T cell in the chemotherapy of NB patients.

The increase of Resting CD4 regulatory T cell is positively correlated with the occurrence and development of neuroblastoma (NB), while the drug papain targets CD4 + T lymphocytes and has a chemotherapy effect on NB.